Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal response

Infection and Immunity

Volumn 82, Issue 1, 2014, Pages 306-315

  Mear, Jean Baptiste ^a   Gosset, Philippe ^a,b,c,d   Kipnis, Eric ^a   Faure, Emmanuel ^a   Dessein, Rodrigue ^a   Jawhara, Samir ^a   Fradin, Chantal ^a   Faure, Karine ^a   Poulain, Daniel ^a   Sendid, Boualem ^a   Guery, Benoit ^a  

^a UNIV LILLE   (France)

^b INSERM U1019   (France)

^c INSERM   (France)

^d Institut Federatif de Recherche 142   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; INNATE IMMUNITY; LUNG INFECTION; LUNG INJURY; LYMPHOID CELL; MACROPHAGE ACTIVATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

EID: 84890824171     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01085-13     Document Type: Article

References (42)

1. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C. 2009. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77:1083-1090. http://dx.doi.org/10.1128/IAI.00815-08.
2. Kipnis E, Sawa T, Wiener-Kronish J. 2006. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36:78-91. http://dx.doi.org/10.1016/j.medmal.2005.10.007.
3. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
4. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. 2010. Bacterial competition: surviving and thriving in the microbial jungle. Nat. Rev. Microbiol. 8:15-25. http://dx.doi.org/10.1038/nrmicro2259.
5. Delisle M-S, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK. 2008. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J. Crit. Care 23:11-17. http://dx.doi.org/10.1016/j.jcrc.2008.01.005.
6. Méar JB, Kipnis E, Faure E, Dessein R, Schurtz G, Faure K, Guery B. 2013. Candida albicans and Pseudomonas aeruginosa interactions: more than an opportunistic criminal association? Med. Mal. Infect. 43:146-151. http://dx.doi.org/10.1016/j.medmal.2013.02.005.
7. Van der Meer JWM, van de Veerdonk FL, Joosten LAB, Kullberg BJ, Netea MG. 2010. Severe Candida spp. infections: new insights into natural immunity. Int. J. Antimicrob. Agents 36:S58-S62. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.013.
8. Poulain D, Jouault T. 2004. Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr. Opin. Microbiol. 7:342-349. http://dx.doi.org/10.1016/j.mib.2004.06.011.
9. Gow NAR, van de Veerdonk FL, Brown AJP, Netea MG. 2012. Candida albicans morphogenesis and host defense: discriminating invasion from colonization. Nat. Rev. Microbiol. 10:112-122. http://dx.doi.org/10.1038/nrmicro2711.
10. Cheng SC, van de Veerdonk FL, Lenardon M, Stoffels M, Plantinga T, Smeekens S, Rizzetto L, Mukaremera L, Preechasuth K, Cavalieri D, Kanneganti TD, van der Meer JWM, Kullberg BJ, Joosten LAB, Gow NAR, Netea MG. 2011. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J. Leukoc. Biol. 90: 357-366. http://dx.doi.org/10.1189/jlb.1210702.
11. Jouault T, Abed-El Behi El M, Martínez-Esparza M, Breuilh L, Trinel P-A, Chamaillard M, Trottein F, Poulain D. 2006. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J. Immunol. 177:4679-4687.
12. Van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJPM, Cheng S-C, Joosten I, van den Berg WB, Williams DL, van der Meer JWM, Joosten LAB, Netea MG. 2009. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 5:329-340. http://dx.doi.org/10.1016/j.chom.2009.02.006.
13. Gaffen SL. 2009. Structure and signaling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556-567. http://dx.doi.org/10.1038/nri2586.
14. Cypowyj S, Picard C, Maródi L, Casanova J-L, Puel A. 2012. Immunity to infection in IL-17-deficient mice and humans. Eur. J. Immunol. 42:2246-2254. http://dx.doi.org/10.1002/eji.201242605.
15. Huang W, Na L, Fidel PL, Schwarzenberger P. 2004. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190:624-631. http://dx.doi.org/10.1086/422329.
16. Laan M, Cui ZH, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh BE, Lindén A. 1999. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162:2347-2352.
17. Kao C-Y, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R. 2004. IL-17 markedly upregulates beta-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J. Immunol. 173:3482-3491.
18. Paget C, Trottein F. 2013. Role of type 1 natural killer T cells in pulmonary immunity. Mucosal Immunol. 6:1054-1067. http://dx.doi.org/10.1038/mi.2013.59.
19. Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, Dickey BF, Tuvim MJ. 2008. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177:1322-1330. http://dx.doi.org/10.1164/rccm.200607-1038OC.
20. Wesselkamper SC, Eppert BL, Motz GT, Lau GW, Hassett DJ, Borchers MT. 2008. NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection. J. Immunol. 181:5481-5489.
21. Ader F, Jawhara S, Nseir S, Kipnis E, Faure K, Vuotto F, Chemani C, Sendid B, Poulain D, Guery B. 2011. Short term Candida albicans colonization reduces Pseudomonas aeruginosa-related lung injury and bacterial burden in a murine model. Crit. Care 15:R150. http://dx.doi.org/10.1186/cc10276.
22. Winsor GL, Lam DKW, Fleming L, Lo R, Whiteside MD, Yu NY, Hancock REW, Brinkman FSL. 2011. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res. 39:D596-D600. http://dx.doi.org/10.1093/nar/gkq869.
23. Jones T, Federspiel NA, Chibana H, Dungan J, Kalman S, Magee BB, Newport G, Thorstenson YR, Agabian N, Magee PT, Davis RW, Scherer S. 2004. The diploid genome sequence of Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 101:7329-7334. http://dx.doi.org/10.1073/pnas.0401648101.
24. Boutoille D, Marechal X, Pichenot M, Chemani C, Guery B, Faure K. 2009. FITC-albumin as a marker for assessment of endothelial permeability in mice: comparison with 125I-albumin. Exp. Lung Res. 35:263-271. http://dx.doi.org/10.1080/01902140802632290.
25. Koh AY, Priebe GP, Ray C, van Rooijen N, Pier GB. 2009. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect. Immun. 77:5300-5310. http://dx.doi.org/10.1128/IAI.00501-09.
26. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14:275-281. http://dx.doi.org/10.1038/nm1710.
27. Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, Shibata N, Grunberg S, Sinha R, Zahm AM, Tardif MR, Sathaliyawala T, Kubota M, Farber DL, Collman RG, Shaked A, Fouser LA, Weiner DB, Tessier PA, Friedman JR, Kiyono H, Bushman FD, Chang K-M, Artis D. 2012. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336: 1321-1325. http://dx.doi.org/10.1126/science.1222551.
28. Lavoie EG, Wangdi T, Kazmierczak BI. 2011. Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect. 13:1133-1145. http://dx.doi.org/10.1016/j.micinf.2011.07.011.
29. Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S, Worthen GS. 2011. IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J. Immunol. 186:3197-3205. http://dx.doi.org/10.4049/jimmunol.1002016.
30. Sonnenberg GF, Fouser LA, Artis D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12:383-390. http://dx.doi.org/10.1038/ni.2025.
31. Bals R, Hiemstra PS. 2004. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur. Respir. J. 23:327-333. http://dx.doi.org/10.1183/09031936.03.00098803.
32. Spits H, Di Santo JP. 2011. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12:21-27. http://dx.doi.org/10.1038/ni.1962.
33. Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. 2011. Inhaled innate immune ligands to prevent pneumonia. Br. J. Pharmacol. 163:195-206. http://dx.doi.org/10.1111/j.1476-5381.2011.01237.x.
34. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. 1995. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155:5483-5486.
35. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. 2000. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165:6107-6115.
36. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914. http://dx.doi.org/10.1074/jbc.M207577200.
37. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Mahapatra Das B, Rouvier E, Golstein P, Banchereau J, Lebecque S. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:2593-2603. http://dx.doi.org/10.1084/jem.183.6.2593.
38. Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. 2011. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol. Med. Microbiol. 61:179-188. http://dx.doi.org/10.1111/j.1574-695X.2010.00764.x.
39. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, Iannitti RG, Bonifazi P, Renauld J-C, Bistoni F, Puccetti P, Romani L. 2010. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 3:361-373. http://dx.doi.org/10.1038/mi.2010.22.
40. Shu Q, Shi Z, Zhao Z, Chen Z, Yao H, Chen Q, Hoeft A, Stuber F, Fang X. 2006. Protection against Pseudomonas aeruginosa pneumonia and sepsisinduced lung injury by overexpression of beta-defensin-2 in rats. Shock 26:365-371. http://dx.doi.org/10.1097/01.shk.0000224722.65929.58.
41. Kumar A, Zhang J, Yu F-SX. 2006. Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. Microbes Infect. 8:380-389. http://dx.doi.org/10.1016/j.micinf.2005.07.006.
42. Cirioni O, Ghiselli R, Tomasinsig L, Orlando F, Silvestri C, Skerlavaj B, Riva A, Rocchi M, Saba V, Zanetti M, Scalise G, Giacometti A. 2008. Efficacy of LI-37 and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to Pseudomonas aeruginosa. Shock 30:443-448. http://dx.doi.org/10.1097/SHK.0b013e31816d2269.